Name | Solcitinib |
---|---|
Synonyms |
N-(5-{4-[(3,3-Dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
UNII-3V7GQ1260K N-(5-{4-[(3,3-dimethylazetidin-1-yl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide G154578 solcitinibum GSK2586184A GLPG0778 Cyclopropanecarboxamide, N-[5-[4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]- solcitinib |
Description | Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis. |
---|---|
Related Catalog | |
Target |
JAK1:9.8 nM (IC50) |
In Vitro | Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C22H23N5O2 |
Molecular Weight | 389.45000 |
Exact Mass | 389.18500 |
PSA | 79.60000 |
LogP | 1.51 |
Index of Refraction | 1.723 |
Storage condition | 2-8℃ |